EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Top advances of the year: Bladder cancer

Andrea B Apolo iD, Saad Atiq, Andre R Kydd iD, Raju Chelluri, Braden Millan iD, Sandeep Gurram iD, Elias Chandran, Nicholas Simon

Cancer · 2025

DOI: 10.1002/cncr.70020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Andrea B Apolo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug‐delivery mechanisms in intravesical therapy for nonmuscle‐invasive bladder cancer and muscle‐invasive bladder cancer (MIBC); (2) immune checkpoint inhibition (ICI) as adjuvant and (3) perioperative therapy in MIBC; (4) circulating tumor DNA as a biomarker in MIBC; to (5) a new standard of care in first‐line metastatic urothelial carcinoma. TAR‐200 is a new intravesical drug‐delivery system that enables controlled release of gemcitabine but may be used with other anticancer drugs to treat nonmuscle‐invasive bladder cancer and MIBC. Two phase 3 studies of adjuvant ICI (nivolumab and pembrolizumab) have both reported a doubling of disease‐free survival in patients with high‐risk MIBC receiving therapy. Perioperative durvalumab, including neoadjuvant therapy plus gemcitabine and cisplatin before radical cystectomy followed by adjuvant durvalumab, demonstrated an improvement in event‐free survival and overall survival for patients with MIBC. Circulating tumor DNA is a promising biomarker to select patients with MIBC for adjuvant ICI therapy. Finally, the combination of enfortumab vedotin, an antibody–drug conjugate, plus pembrolizumab doubled overall survival compared with standard gemcitabine plus platinum in patients with metastatic urothelial carcinoma and has been implemented in treatment guidelines in the United States, Europe, and Asia as the new standard of care in this setting, transforming the treatment landscape for bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellHumansImmune Checkpoint InhibitorsBiomarkers, TumorNeoadjuvant TherapyGemcitabineDeoxycytidineCirculating Tumor DNAChemotherapy, AdjuvantCystectomyAdministration, IntravesicalAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

TAR‐200adjuvant therapybladder cancercirculating tumor DNA (ctDNA)first‐line therapyimmune checkpoint inhibitorsimmunotherapyperioperative therapyurothelial carcinoma

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorGemcitabineDeoxycytidineCirculating Tumor DNApembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Andrea B Apolo, Andre R Kydd, Braden Millan, Sandeep Gurram

Zitieren

APA

Apolo, A. B., Atiq, S., Kydd, A. R., Chelluri, R., Millan, B., Gurram, S., Chandran, E., & Simon, N. (2025). Top advances of the year: Bladder cancer. Cancer. https://doi.org/10.1002/cncr.70020

Vancouver

Apolo AB, Atiq S, Kydd AR, Chelluri R, Millan B, Gurram S, et al. Top advances of the year: Bladder cancer. Cancer. 2025. doi:10.1002/cncr.70020

BibTeX
@article{Apolo2025,
  author = {Apolo, Andrea B and Atiq, Saad and Kydd, Andre R and Chelluri, Raju and Millan, Braden and Gurram, Sandeep and Chandran, Elias and Simon, Nicholas},
  title = {Top advances of the year: Bladder cancer},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70020}
}
Kostenlos starten →